Mostrando 10 resultados de: 10
Filtros aplicados
Subtipo de publicación
Other(10)
Publisher
American Society of Clinical Oncology(3)
AMER SOC CELL BIOLOGY(1)
Elsevier(1)
LWW(1)
SPRINGER(1)
Área temáticas
Enfermedades(9)
Farmacología y terapéutica(6)
Medicina y salud(3)
Fisiología humana(2)
Ginecología, obstetricia, pediatría, geriatría(2)
Origen
google(10)
A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer.
OtherAbstract:Palabras claves:Autores:Alejandra PérezFuentes:googleA phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer
OtherAbstract: This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapyPalabras claves:Autores:Alejandra PérezFuentes:googleCorrelation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
OtherAbstract: LBA509 Background: Everolimus (EVE) plus exemestane (EXE) more than doubled progression-free survivaPalabras claves:Autores:Alejandra PérezFuentes:googleCorrelative analysis of genetic alterations and everolimus benefit in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer …
OtherAbstract: Purpose To explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to iPalabras claves:Autores:Alejandra PérezFuentes:googleDirect inhibition of the Glut1 hexose transporter by resveratrol.
OtherAbstract:Palabras claves:Autores:Alejandra PérezFuentes:googleIncidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
OtherAbstract: Background In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, dPalabras claves:Autores:Alejandra PérezFuentes:googleImpact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients …
OtherAbstract: 1048 Background: A preferred NAC regimen for HER2-negative BC is DDAC for 4 cycles followed by 12 wePalabras claves:Autores:Alejandra PérezFuentes:googlePegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
OtherAbstract: Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicinPalabras claves:Autores:Alejandra PérezFuentes:googlePhase II Trial of Infusional Cyclophosphamide, Idarubicin, and Etoposide in Poor Prognosis Non-Hodgkin’s Lymphoma
OtherAbstract: The purpose of this study was to determine the complete response (CR) rate, failure-free survival (FPalabras claves:Autores:Alejandra PérezFuentes:googleUSE OF A CUSTOM PHARMACOGENETICS SNP-ARRAY (PHARMARRAY (R)) FOR CYP2C19 GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) PATIENTS FOR ASPERGILLOSIS …
OtherAbstract:Palabras claves:Autores:Alejandra PérezFuentes:google